摘要
在过去的一些年里,使用全基因组关联分析已使得对高血压必须的主要基因机制确认成为可能。全基因组关联分析结果已帮助确认许多被认为不与血压或者原发性高血压相关的基因和附近基因。但是,考虑到在临床中预期的巨大改进结果,数十亿的美元已经被花费在各种全基因组关联分析中,进展却显得有些缓慢。全基因组关联分析成功的相对缺乏可归因于几个因素。首先,可能是各种GWAS纳入的人数不充分,因而限制了检测到额外标志物的能力;第二,由于有风险等位基因以一个平稳的增加量被不断发现,他们的判别能力和可用作预测性的标志物是非常低的。控制组选择中不同的困难和不可重复性也是在使用GWAS时存在的问题。本文综述了最近使用高血压的GWAS的进展以及用于确定许多原发性高血压相关的轨迹。在本综述中,我们讨论高血压的GWAS的进展和问题。
关键词: 血压,基因组,全基因组关联分析研究,高血压。
Current Medicinal Chemistry
Title:Progress and Issues of the Genome-Wide Association Study for Hypertension
Volume: 22 Issue: 8
Author(s): Shuo Pan, Hiromu Naruse and Tomohiro Nakayama
Affiliation:
关键词: 血压,基因组,全基因组关联分析研究,高血压。
摘要: Over the past few years, use of the genome-wide association study (GWAS) has made it possible to identify the primary genetic mechanisms of essential hypertension. GWAS results have helped identify many loci in or near genes that generally were not expected to be associated with blood pressure or essential hypertension. However, considering the great expectations of improving clinical outcomes and the billions of dollars that have been spent on various GWASs, the progress made so far has been slow. There are several factors that could be responsible for the relative lack of success of GWASs. First, it is possible that the number of people enrolled in the various GWASs was not enough, thereby limiting the power to detect additional markers. Second, although the alleles that are associated with a modest increase in risk are constantly being found, their discriminatory ability and use as predictive markers has been quite low. Difficulties with control group selection along with unrepeatability have also been problematic when using GWASs. The current paper summarizes the recent progress attained when using a GWAS of hypertension to identify the many loci associated with essential hypertension. In this review, we discuss the progress and issues of a GWAS for hypertension.
Export Options
About this article
Cite this article as:
Shuo Pan, Hiromu Naruse and Tomohiro Nakayama , Progress and Issues of the Genome-Wide Association Study for Hypertension, Current Medicinal Chemistry 2015; 22 (8) . https://dx.doi.org/10.2174/0929867321666141216124537
DOI https://dx.doi.org/10.2174/0929867321666141216124537 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Current Pharmaceutical Design Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension
Current Hypertension Reviews Subject Index to Volume 9
Current Pharmaceutical Design Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke
Current Neurovascular Research Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Mini-Reviews in Medicinal Chemistry Metformin Toxicity: A Report of 204 Cases from Iran.
Current Drug Safety The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Update on the Therapies of Severe Lupus Nephritis
Current Rheumatology Reviews Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Current Medicinal Chemistry CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design Intrauterine Effects of Impaired Lipid Homeostasis in Pregnancy Diseases
Current Medicinal Chemistry Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery EDITORIAL [Hot Topic: Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Ophthalmic Conditions (Guest Editor: Michael W. Stewart)]
Current Drug Therapy Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Targeting Tau Hyperphosphorylation <I>via</I> Kinase Inhibition: Strategy to Address Alzheimer's Disease
Current Topics in Medicinal Chemistry Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research The Role of EC-IC Bypass in Critical Cerebral Hemodynamics of Different Origin
Current Hypertension Reviews Goal Directed Fluid Therapy
Current Pharmaceutical Design